|
1
|
Fennell DA, Gaudino G, O’Byrne KJ, Mutti L
and van Meerbeeck J: Advances in the systemic therapy of malignant
pleural mesothelioma. Nat Clin Pract Oncol. 5:136–147. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wicki A and Christofori G: The potential
role of podoplanin in tumour invasion. Br J Cancer. 96:1–5. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ramirez MI, Millien G, Hinds A, Cao Y,
Seldin DC and Williams MC: T1alpha, a lung type I cell
differentiation gene, is required for normal lung cell
proliferation and alveolus formation at birth. Dev Biol. 256:61–72.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Schacht V, Ramirez MI, Hong YK, et al:
T1alpha/podoplanin deficiency disrupts normal lymphatic vasculature
formation and causes lymphedema. EMBO J. 22:3546–3556. 2003.
View Article : Google Scholar
|
|
5
|
Breiteneder-Geleff S, Soleiman A, Kowalski
H, et al: Angiosarcomas express mixed endothelial phenotypes of
blood and lymphatic capillaries: podoplanin as a specific marker
for lymphatic endothelium. Am J Pathol. 154:385–394. 1999.
View Article : Google Scholar
|
|
6
|
Kato Y, Kaneko M, Sata M, Fujita N, Tsuruo
T and Osawa M: Enhanced expression of Aggrus (T1alpha/podoplanin),
a platelet-aggregation-inducing factor in lung squamous cell
carcinoma. Tumour Biol. 26:195–200. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Martin-Villar E, Scholl FG, Gamallo C, et
al: Characterization of human PA2.26 antigen (T1alpha-2,
podoplanin), a small membrane mucin induced in oral squamous cell
carcinomas. Int J Cancer. 113:899–910. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Schacht V, Dadras SS, Johnson LA, Jackson
DG, Hong YK and Detmar M: Up-regulation of the lymphatic marker
podoplanin, a mucin-type transmembrane glycoprotein, in human
squamous cell carcinomas and germ cell tumors. Am J Pathol.
166:913–921. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shibahara J, Kashima T, Kikuchi Y, Kunita
A and Fukayama M: Podoplanin is expressed in subsets of tumors of
the central nervous system. Virchows Arch. 448:493–499. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wicki A, Lehembre F, Wick N, Hantusch B,
Kerjaschki D and Christofori G: Tumor invasion in the absence of
epithelial-mesenchymal transition: podoplanin-mediated remodeling
of the actin cytoskeleton. Cancer Cell. 9:261–272. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kimura N and Kimura I: Podoplanin as a
marker for mesothelioma. Pathol Int. 55:83–86. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ordonez NG: Podoplanin: a novel diagnostic
immunohistochemical marker. Adv Anat Pathol. 13:83–88. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hinterberger M, Reineke T, Storz M, Weder
W, Vogt P and Moch H: D2-40 and calretinin - a tissue microarray
analysis of 341 malignant mesotheliomas with emphasis on
sarcomatoid differentiation. Mod Pathol. 20:248–255. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Padgett DM, Cathro HP, Wick MR and Mills
SE: Podoplanin is a better immunohistochemical marker for
sarcomatoid mesothelioma than calretinin. Am J Surg Pathol.
32:123–127. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mimura T, Ito A, Sakuma T, et al: Novel
marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal
set of immunodiagnostic markers for pleural mesothelioma. Cancer.
109:933–938. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Marchevsky AM: Application of
immunohistochemistry to the diagnosis of malignant mesothelioma.
Arch Pathol Lab Med. 132:397–401. 2008.PubMed/NCBI
|
|
17
|
Kawaguchi H, El-Naggar AK,
Papadimitrakopoulou V, et al: Podoplanin: a novel marker for oral
cancer risk in patients with oral premalignancy. J Clin Oncol.
26:354–360. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Horiguchi A, Ito K, Sumitomo M, Kimura F,
Asano T and Hayakawa M: Intratumoral lymphatics and lymphatic
invasion are associated with tumor aggressiveness and poor
prognosis in renal cell carcinoma. Urology. 71:928–932. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mishima K, Kato Y, Kaneko MK, Nishikawa R,
Hirose T and Matsutani M: Increased expression of podoplanin in
malignant astrocytic tumors as a novel molecular marker of
malignant progression. Acta Neuropathol. 111:483–488. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Martin-Villar E, Megias D, Castel S,
Yurrita MM, Vilaro S and Quintanilla M: Podoplanin binds ERM
proteins to activate RhoA and promote epithelial-mesenchymal
transition. J Cell Sci. 119:4541–4553. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kunita A, Kashima TG, Morishita Y, et al:
The platelet aggregation-inducing factor aggrus/podoplanin promotes
pulmonary metastasis. Am J Pathol. 170:1337–1347. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Deroanne CF, Hamelryckx D, Ho TT, et al:
Cdc42 downregulates MMP-1 expression by inhibiting the ERK1/2
pathway. J Cell Sci. 118:1173–1183. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zeng ZS, Shu WP, Cohen AM and Guillem JG:
Matrix metalloproteinase-7 expression in colorectal cancer liver
metastases: evidence for involvement of MMP-7 activation in human
cancer metastases. Clin Cancer Res. 8:144–148. 2002.PubMed/NCBI
|
|
24
|
Tutton MG, George ML, Eccles SA, Burton S,
Swift RI and Abulafi AM: Use of plasma MMP-2 and MMP-9 levels as a
surrogate for tumour expression in colorectal cancer patients. Int
J Cancer. 107:541–550. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Klominek J, Baskin B and Hauzenberger D:
Platelet-derived growth factor (PDGF) BB acts as a chemoattractant
for human malignant mesothelioma cells via PDGF receptor
beta-integrin alpha3beta1 interaction. Clin Exp Metastasis.
16:529–539. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mueller L, Goumas FA, Himpel S, Brilloff
S, Rogiers X and Broering DC: Imatinib mesylate inhibits
proliferation and modulates cytokine expression of human
cancer-associated stromal fibroblasts from colorectal metastases.
Cancer Lett. 250:329–338. 2007. View Article : Google Scholar
|
|
27
|
Faried A, Faried LS, Kimura H, et al: RhoA
and RhoC proteins promote both cell proliferation and cell invasion
of human oesophageal squamous cell carcinoma cell lines in vitro
and in vivo. Eur J Cancer. 42:1455–1465. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Spugnini EP, Cardillo I, Verdina A, et al:
Piroxicam and cisplatin in a mouse model of peritoneal
mesothelioma. Clin Cancer Res. 12:6133–6143. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhong J, Gencay MM, Bubendorf L, et al:
ERK1/2 and p38 MAP kinase control MMP-2, MT1-MMP, and TIMP action
and affect cell migration: a comparison between mesothelioma and
mesothelial cells. J Cell Physiol. 207:540–552. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gorelik E, Bere WW and Herberman RB: Role
of NK cells in the antimetastatic effect of anticoagulant drugs.
Int J Cancer. 33:87–94. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Scholl FG, Gamallo C, Vilaró S and
Quintanilla M: Identification of PA2.26 antigen as a novel
cell-surface mucin-type glycoprotein that induces plasma membrane
extensions and increased motility in keratinocytes. J Cell Sci.
112:4601–4613. 1999.PubMed/NCBI
|
|
32
|
Suzuki-Inoue K, Kato Y, Inoue O, et al:
Involvement of the snake toxin receptor CLEC-2, in
podoplanin-mediated platelet activation, by cancer cells. J Biol
Chem. 282:25993–26001. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Edwards JG, McLaren J, Jones JL, Waller DA
and O’Byrne KJ: Matrix metalloproteinases 2 and 9 (gelatinases A
and B) expression in malignant mesothelioma and benign pleura. Br J
Cancer. 88:1553–1559. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Baker SJ and Reddy EP: Modulation of life
and death by the TNF receptor superfamily. Oncogene. 17:3261–3270.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wada T and Penninger JM: Mitogen-activated
protein kinases in apoptosis regulation. Oncogene. 23:2838–2849.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lee S, Yoon S and Kim DH: A high nuclear
basal level of ERK2 phosphorylation contributes to the resistance
of cisplatin-resistant human ovarian cancer cells. Gynecol Oncol.
104:338–344. 2007. View Article : Google Scholar : PubMed/NCBI
|
